EvlaBio’s website
2 known investors
EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
Investors · 2
Frequently asked questions
- What does EvlaBio’s website do?
- EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
- Who are EvlaBio’s website's investors?
- EvlaBio’s website's investors include AdBio partners, Kurma Partners.